Attention around pharmacovigilance transformation potential has tended to focus on automating discrete steps in the ...

Workforce scaling is being addressed through parallel levers, including regional branding, early STEM pipeline cultivation, ...

A Class II recall was initiated for duloxetine lots after N-nitroso-duloxetine exceeded FDA intake limits, reflecting low acute clinical risk but regulatory nonconformance. Nitrosamine issues ...

Oncology remains the leading M&A magnet, with ASCO data catalyzing interest in new combinations and next-generation ...

FDA’s durable expectation is that AI outputs can aid drafting, but must be reviewed and cleared by an authorized QU ...

Eli Lilly was attracted by a deliberately cultivated life sciences strategy anchored in a region where manufacturing ...

At CPHI Americas 2026, PharmTech spoke with Dr. Molly Klote, president and CEO, Klote Medical Research Advisors, and ...

According to the USP report, the duration of drug shortages increased to 5.3 years in 2025. This is a result of new shortages ...

The US Pharmacopeia’s 2025 annual drug shortages report found that while the total number of shortages declined by 23% in ...

Kristin Ciriello Pothier, KPMG US, discusses biopharma dealmaking shifting toward strategic precision, with oncology, GLP-1s, and manufacturing complexity reshaping M&A valuations in 2026.

Clinical data warehouses maximize veracity via schema-on-write and ACID guarantees, but ETL rework, limited modality support, ...